Increased colistin resistance of Acinetobacter species in intensive care unit-acquired infections in a tertiary care hospital
Increased colistin resistance
DOI:
https://doi.org/10.3823/815Keywords:
Colistin, Intensive care unit, Acinetonacter baumannii antibiotic resistanceAbstract
Background: The aim of our study was to evaluate the antimicrobial resistance rates among pathogen microorganisms especially colistin resistant rates of Acinetobacter baumannii in intensive care unit (ICU)-acquired infections and to determine infection-specific correct treatment strategies.
Methods: The data of adult and newborn infant patients diagnosed with ICU-acquired infection in a tertiary education and research hospital in Bursa in 2014 and 2016 were analyzed, retrospectively.
Results: Acinetobacter baumannii was the most frequent pathogen of ICU-acquired infections in 2014 and 2016. There was a significant increase in colistin (CO) resistance rates in A. baumanii (0.0%-6.8%). A significant increase in CO, cefepime (FEP), ciprofloxacin (CIP) resistance rates was established in all gram negative bacteria (0.0%-7.9%, 50.0%-91.9%, 54.7%-74.6%), respectively. A significant increase in the rate of detection of A. baumanii as the pathogen microorganism in respiratory tract infection (RTI) was established (53.9% -79.5%). In addition, the average ventilator-associated pneumonia (VIP) infection rate also increased in 2016 compared to 2014 (VIP rate 2014: 7.12, 2016: 7.45, per 1000 ventilator days). A significant decrease in the rate of detection of all gram negative microorganisms in the surgical site infection (SSI), and a significant increase in the rate of detection of all gram positive microorganisms in the SSI was determined.
Conclusion: Increased antimicrobial resistance, especially increased colistin resistance rates in ICU-acquired infections, necessitates the creation of new strategies in empirical therapy. Detection of antimicrobial resistance profiles of local and infectious pathogen microorganisms in ICUs is a good guide for correct antimicrobial management.
References
References
Mitharwal SM, Yaddanapudi S, Bhardwaj N, Gautam V, Biswal M, et al. Intensive care unit-acquired infections in a tertiary care hospital: An epidemiologic survey and influence on patient outcomes. Am J Infect Control 2016; 44: 113-7.
Ariffin N, Hasan H, Ramli N, Ibrahim NR, Taib F, et al. Comparison of antimicrobial resistance in neonatal and adult intensive care units in a tertiary teaching hospital. Am J Infect Control 2012; 40: 572-5.
Axente C, Licker M, Moldovan R, Hogea E, Muntean D, Horhat F, Bedreag O, Sandesc D, Papurica M, Dugaesescu D, Voicu M, Baditoiu L. Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit. BMC Infect Dis. 2017; 17: 358. doi: 10.1186/s12879-017-2440-7.
Fraimow HS, Tsigrelis C. Antimicrobial resistance in the intensive care unit: mechanisms, epidemiology, and management of specific resistant pathogens. Crit Care Clin 2011; 27: 163-205.
Ritchie DJ, Alexander BT, Finnegan PM. New antimicrobial agents for use in the intensive care unit. Infect Dis Clin North Am 2009; 23: 665-81.
Cassir N, Rolain JM, Brouqui P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014; 5: 551.
Yilmaz GR, Dizbay M, Guven T, Pullukcu H, Tasbakan M, et al. Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study. Ann Saudi Med 2016; 36: 216-22.
Lee JY, Choi MJ, Choi HJ, Ko KS. Preservation of acquired colistin resistance in gram-negative bacteria. Antimicrob Agents Chemother2015; 60: 609-12.
Halaby T, Al Naiemi N, Kluytmans J, van der Palen J, Vandenbroucke-Grauls CM. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 2013; 57: 3224-9.
Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings. MMWR Morb Mortal Wlkly Rep. 2002; 51: 343.
Beardsley J, Williamson J, Johnson J, et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital acquired pneumonia. Chest 2006;130:787-93.
Arroyo LA, Garcia-Curiel A, Pachon- Ibanez ME, van den Barselaar M, Nordmann P, et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 2005; 43: 903-5.
Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012; 67: 1607-15.
Beriş FŞ, Budak EE, Gülek D, Uzun A, Çizmeci Z, et aal. Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of Acinetobacter baumannii collected from different regions of Turkey: a multicenter study. Mikrobiyol Bul 2016; 50: 511-21.
Karagöz A, Baran I, Aksu N, Acar S, Durmaz R. Characterization and determination of antibiotic resistance profiles of a single clone Acinetobacter baumannii strains isolated from blood cultures. Mikrobiyol Bul 2014; 48: 566-76.
Sligl WI, Dragan T, Smith SW. Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes. Int J Infect Dis. 2015; 37: 129-34.
Clark NM, Patterson J, Lynch JP. Antimicrobial resistance among gram-negative organisms in the intensive care unit. Curr Opin Crit Care 2003; 9: 413-23.
Shojaei L, Mohammadi M, Beigmohammadi MT, Doomanlou M, Abdollahi A, et al. Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients. Iran J Microbiol. 2016; 8: 288-29.
Gu WJ, Wang F, Tang L, Bakker J, Liu JC. Colistin for the treatment of ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: a systematic review and meta-analysis. Int J Antimicrob Agents 2014; 44: 477-85.
Tekin R, Dal T, Pirinccioglu H, Oygucu SE. A 4-year surveillance of device-associated nosocomial infections in a neonatal intensive care unit. Pediatr Neonatol 2013; 54: 303-8.
El-Saed A, Balkhy HH, Al-Dorzi HM, Khan R, Rishu AH, Arabi YM. Acinetobacter is the most common pathogen associated with late-onset and recurrent ventilator-associated pneumonia in an adult intensive care unit in Saudi Arabia. Int J Infect Dis. 2013; 17: 696-701.
Leblebicioglu H, Erben N, Rosenthal VD, Atasay B, Erbay A, et al. International Nosocomial Infection Control Consortium (INICC) national report on device-associated infection rates in 19 cities of Turkey, data summary for 2003-2012. Ann Clin Microbiol Antimicrob 2014: 18; 13:51.
Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 2008; 36: 1-12.
Downloads
Published
Issue
Section
License
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 3.0 License ©
Copyright policies & self-archiving
This is our Copyright Policy. We are a RoMEO green journal.
| Author's Pre-print: |  author can archive pre-print (ie pre-refereeing) |
| Author's Post-print: | author can archive post-print (ie final draft post-refereeing) |
| Publisher's Version/PDF: | author can archive publisher's version/PDF |
